
A crossover study (NCT06615869) confirmed the bioequivalence of a new 400 mg molnupiravir tablet to the reference capsules. Key pharmacokinetic parameters met bioequivalence criteria (0.80–1.25). Food intake had no significant impact on absorption, and an alternative tablet formulation (F2) showed similar pharmacokinetics. Molnupiravir was well tolerated in all forms, supporting the 400 mg tablet as a viable alternative to capsules.
Like
Save
Share